IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 5, 2008, Pages 576-582

  Dupuis, L Lee ^a,b,c   Sibbald, Cathryn ^b   Schechter, Tal ^b   Ansari, Marc ^d   Gassas, Adam ^b   Théorêt, Yves ^d,e   Kassir, Nastya ^e   Champagne, Martin A ^d,e   Doyle, John ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Area under the curve; Busulfan; Limited sampling strategy; Pediatrics; Pharmacokinetics

Indexed keywords

BUSULFAN; LORAZEPAM; MIDAZOLAM; PHENYTOIN;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MULTIPLE LINEAR REGRESSION ANALYSIS; MYELODYSPLASTIC SYNDROME; PROCESS DEVELOPMENT; RELIABILITY; SAMPLING; SEIZURE; VALIDATION STUDY;

ADOLESCENT; AREA UNDER CURVE; BUSULFAN; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LINEAR MODELS; SAMPLE SIZE;

EID: 41849114942     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.03.002     Document Type: Article

References (10)

1. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17 (1996) 225-230
2. Grochow L.B. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20 (1993) 18-25
3. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16 (1995) 31-42
4. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89 (1997) 3055-3060
5. Hassan M., and Ehrsson H. Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr A 277 (1983) 374-380
6. Chen T.L., Grochow L.B., Hurowitz L.A., and Brundrett R.B. Determination of busulfan in human plasma by gas chromatography with electron-capture detection. J Chromatogr A 425 (1988) 303-309
7. Rifai N., Sakamoto M., Lafi M., and Guinan E. Measurement of plasma busulfan concentration by high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 19 (1997) 169-174
8. Vaughan W.P., Carey D., Perry S., Westfall A.O., and Salzman D.E. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 8 (2002) 619-624
9. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986) 307-310
10. Nguyen L., Leger F., Lennon S., and Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 57 (2006) 191-198